Publications by authors named "Alexander Kohlmann"

98Publications

Olaparib for Metastatic Castration-Resistant Prostate Cancer.

N Engl J Med 2020 05 28;382(22):2091-2102. Epub 2020 Apr 28.

From the Institute of Cancer Research and Royal Marsden Hospital, London (J. de Bono), and AstraZeneca, Translational Medicine, Cambridge (C.A.A.) - all in the United Kingdom; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital, Barcelona (J.M.), the Spanish National Cancer Research Center, Madrid (D.O.), and Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Malaga (D.O.) - all in Spain; Institut Gustave Roussy, University of Paris Sud, Villejuif (K.F.), and the Department of Medical Oncology, Centre Hospitalier Universitaire Besançon, Besançon (A.T.-V.) - all in France; Centre Hospitalier de l'Université de Montréal-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal (F.S.), and BC Cancer Agency, Vancouver (K.N.C.) - all in Canada; Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S.S.); Tulane University School of Medicine, New Orleans (O.S.); Huntsman Cancer Institute, University of Utah Comprehensive Cancer Center, Salt Lake City (N.A.); John Wayne Cancer Institute, Santa Monica, CA (P.T.); Radboud University Medical Center, Nijmegen, the Netherlands (N.M.); AstraZeneca, Global Medicines Development, Oncology, Gaithersburg, MD (C.G., J.K., W.W.); Merck, Kenilworth, NJ (J. Burgents); AstraZeneca, Precision Medicine, Oncology Research and Development, Gaithersburg, MD (A.K.); and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago (M.H.).

View Article and Find Full Text PDF
May 2020

Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology.

Crit Rev Oncol Hematol 2018 Jun 29;126:64-79. Epub 2018 Mar 29.

Center of Laboratory Medicine (ZLM)/University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, Bern, Switzerland; University Department of Hematology, Inselspital, Bern University Hospital, Bern, Switzerland. Electronic address:

View Article and Find Full Text PDF
June 2018

Current status and trends in the diagnostics of AML and MDS.

Blood Rev 2018 11 27;32(6):508-519. Epub 2018 Apr 27.

University Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland; Center of Laboratory Medicine (ZLM)/University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, Bern, Switzerland. Electronic address:

View Article and Find Full Text PDF
November 2018

A comparative study of germline BRCA1 and BRCA2 mutation screening methods in use in 20 European clinical diagnostic laboratories.

Br J Cancer 2017 Aug 27;117(5):710-716. Epub 2017 Jul 27.

European Molecular Genetics Quality Network, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester M13 9WL, UK.

View Article and Find Full Text PDF
August 2017

Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients.

PLoS One 2017 4;12(5):e0175779. Epub 2017 May 4.

Personalised Healthcare and Biomarkers, Innovative Medicines and Early Development, AstraZeneca, Cambridge, United Kingdom.

View Article and Find Full Text PDF
September 2017

A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts.

Leuk Res 2017 05 4;56:82-87. Epub 2017 Feb 4.

IBMCC, Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, Spain; IBSAL, Instituto de Investigación Biomédica de Salamanca, Spain; Hospital Universitario de Salamanca, Spain. Electronic address:

View Article and Find Full Text PDF
May 2017

Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC).

PLoS One 2016 26;11(2):e0150197. Epub 2016 Feb 26.

Personalised Healthcare & Biomarkers, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Darwin Building, 310 Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, United Kingdom.

View Article and Find Full Text PDF
July 2016

Mutational profiling in patients with MDS: ready for every-day use in the clinic?

Best Pract Res Clin Haematol 2015 Mar 12;28(1):32-42. Epub 2014 Nov 12.

MLL Munich Leukemia Laboratory, Munich, Germany. Electronic address:

View Article and Find Full Text PDF
March 2015

Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome.

Nat Commun 2015 Jan 14;6:6042. Epub 2015 Jan 14.

1] Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, 12-01, Singapore 117599, Singapore [2] Cedars-Sinai Medical Center, Division of Hematology/Oncology, UCLA School of Medicine, Los Angeles, California 90048, USA [3] National University Cancer Institute, National University Hospital Singapore, Singapore 119228, Singapore.

View Article and Find Full Text PDF
January 2015